Allspring Global Investments Holdings LLC decreased its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 55.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,484 shares of the company’s stock after selling 8,064 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Y-mAbs Therapeutics were worth $44,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in Y-mAbs Therapeutics by 924.1% during the first quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company’s stock worth $30,000 after purchasing an additional 5,323 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Y-mAbs Therapeutics by 248.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,513 shares of the company’s stock valued at $99,000 after acquiring an additional 4,645 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Y-mAbs Therapeutics by 172.5% in the second quarter. BNP Paribas Arbitrage SA now owns 7,980 shares of the company’s stock worth $121,000 after acquiring an additional 5,052 shares during the period. Denali Advisors LLC purchased a new position in Y-mAbs Therapeutics in the first quarter worth approximately $42,000. Finally, Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics during the second quarter worth $160,000. Hedge funds and other institutional investors own 45.45% of the company’s stock.
Y-mAbs Therapeutics Trading Up 2.1 %
Shares of NASDAQ YMAB opened at $5.26 on Friday. The stock has a market cap of $229.44 million, a P/E ratio of -5.91 and a beta of 0.67. The business’s fifty day simple moving average is $5.34 and its 200-day simple moving average is $6.52. Y-mAbs Therapeutics, Inc. has a 12-month low of $2.70 and a 12-month high of $15.89.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their price target on Y-mAbs Therapeutics from $8.00 to $7.00 and set an “underweight” rating for the company in a report on Tuesday, August 22nd. Canaccord Genuity Group lifted their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, July 25th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, August 14th. Finally, Morgan Stanley lowered their price objective on shares of Y-mAbs Therapeutics from $7.00 to $5.00 and set an “underweight” rating for the company in a research report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.63.
Read Our Latest Stock Analysis on YMAB
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Read More
- Five stocks we like better than Y-mAbs Therapeutics
- How to Invest in Electric Cars
- Institutions Buy Consumer Staples, is the Bottom in?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Fastenal or Simpson Manufacturing: Which is the Better Buy?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Can These 3 Semiconductor Stocks Outpace Nvidia’s Growth?
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
